Next, we describe current therapeutic approaches to the metabolic syndrome axis and discuss how various treatment classes, including GLP-1 receptor agonists and triple G triagonists (combined glucagon, glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptide receptor agonists), may transform our understanding of the physiological interconnectedness of these diseases. Here, GCG is linked to metabolic syndrome.